GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
This Registry will enroll subjects who have achieved an SVR after receiving at least one oaV while participating in a Gilead-sponsored hepatitis C clinical trial. The definition of an SVR is defined in the initial Gilead-sponsored treatment protocol.
once enrolled, subjects will be followed for up to 3 years. a Baseline visit will be scheduled within 90 days from the last visit in the Gilead-sponsored treatment protocol. Subsequent visits will occur at Weeks 24, 48, 72, 96, 120 and 144. at each visit, subjects will have a blood sample collected for HCV Rna, viral sequencing, liver function tests, platelets, coagulation test and [RegisteredTM]-fetoprotein. in addition, a quality of life survey will be completed at each visit.
1. Willing and able to provide written informed consent;
2. Have previously participated in a Gilead-sponsored hepatitis C study and received at least
one Gilead OAV;
3. Have achieved SVR in a Gilead-sponsored study, as defined in the original treatment protocol;
4. Be willing and able to comply with the visit schedule and protocol-mandated procedures.